{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:11:34Z","timestamp":1768781494996,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","amjmedsci.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.amjms.2024.07.021","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T08:58:33Z","timestamp":1720947513000},"page":"24-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of mycophenolate mofetil for the treatment of fibrotic hypersensitivity pneumonitis"],"prefix":"10.1016","volume":"369","author":[{"given":"Ana","family":"Casal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Su\u00e1rez-Antelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Lado-Baleato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja","family":"Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda E.","family":"Toubes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Rodr\u00edguez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2024.07.021_bib0001","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/00004728-200011000-00025","article-title":"Hypersensitivity pneumonitis: patterns on high-resolution CT","volume":"24","author":"Patel","year":"2000","journal-title":"J Comput Assist Tomogr"},{"issue":"5","key":"10.1016\/j.amjms.2024.07.021_bib0002","first-page":"v1","article-title":"Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.amjms.2024.07.021_bib0003","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Resp Med"},{"key":"10.1016\/j.amjms.2024.07.021_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0169-2021","article-title":"Diagnosis, course and management of hypersensitivity pneumonitis","volume":"31","author":"Hamblin","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.amjms.2024.07.021_bib0005","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/CM9.0000000000000256","article-title":"Clinical characteristics and outcomes of hypersensitivity pneumonitis: a population-based study in China","volume":"132","author":"Wang","year":"2019","journal-title":"Chin Med J"},{"key":"10.1016\/j.amjms.2024.07.021_bib0006","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults. An official ATS\/JRS\/ALAT clinical practice guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjms.2024.07.021_bib0007","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.chest.2021.03.066","article-title":"Executive summary diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report","volume":"160","author":"Fern\u00e1ndez-P\u00e9rez","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2024.07.021_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccm.2021.03.007","article-title":"Management of Fibrotic Hypersensitivity Pneumonitis","volume":"42","author":"Barnes","year":"2021","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.amjms.2024.07.021_bib0009","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2024.07.021_bib0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/thoraxjnl-2017-210035","article-title":"Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis","volume":"73","author":"Gimenez","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.amjms.2024.07.021_bib0011","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2024.07.021_bib0012","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1183\/09031936.05.00035005","article-title":"Standardisation of the measurement of lung volumes","volume":"26","author":"Wanger","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2024.07.021_bib0013","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1183\/09031936.98.11061354","article-title":"References values for forced spirometry. Group of the European Community Respiratory Health Survey","volume":"11","author":"Roca","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2024.07.021_bib0014","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1183\/09031936.95.08030492","article-title":"Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society","volume":"8","author":"Stocks","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2024.07.021_bib0015","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the national Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (Pro-CtCae)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.amjms.2024.07.021_bib0016","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society Series B"},{"key":"10.1016\/j.amjms.2024.07.021_bib0017","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jamia\/ocz228","article-title":"A tutorial on calibration measurements and calibration models for clinical prediction models","volume":"27","author":"Huang","year":"2020","journal-title":"Journal of the American Medical Informatics Association"},{"key":"10.1016\/j.amjms.2024.07.021_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"Journal of Statistical Software"},{"key":"10.1016\/j.amjms.2024.07.021_bib0019","unstructured":"Harrell Jr FE. rms: Regression Modeling Strategies. R package version 6.5-0, https:\/\/CRAN.R-project.org\/package=rms. 2023."},{"key":"10.1016\/j.amjms.2024.07.021_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC bioinformatics"},{"key":"10.1016\/j.amjms.2024.07.021_bib0021","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","article-title":"Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis","volume":"151","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2024.07.021_bib0022","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1164\/ajrccm\/147.4.793","article-title":"Recovery of pulmonary function in farmer's lung. A five-year follow-up study","volume":"147","author":"Kokkarinen","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.amjms.2024.07.021_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jcm8010014","article-title":"Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort a single-centre cohort study","volume":"8","author":"De Sadeleer","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjms.2024.07.021_bib0024","first-page":"251","article-title":"Walking the path of treatable traits in interstitial lung diseases","volume":"24","author":"Amati","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.amjms.2024.07.021_bib0025","doi-asserted-by":"crossref","first-page":"00016","DOI":"10.1183\/23120541.00016-2017","article-title":"Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis","volume":"3","author":"Adegunsoye","year":"2017","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.amjms.2024.07.021_bib0026","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjms.2024.07.021_bib0027","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1513\/AnnalsATS.202108-954RL","article-title":"Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease","volume":"19","author":"Wong","year":"2022","journal-title":"Annals ATS"},{"key":"10.1016\/j.amjms.2024.07.021_bib0028","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.amjms.2024.07.021_bib0029","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/crj.13086","article-title":"Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis\u2014A single-centre Experience","volume":"13","author":"Fiddler","year":"2019","journal-title":"Clin Respir J"},{"key":"10.1016\/j.amjms.2024.07.021_bib0030","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjms.2024.07.021_bib0031","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II), a double-blind, parallel group, randomized controlled trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.amjms.2024.07.021_bib0032","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/1756-185X.13035","article-title":"Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease","volume":"20","author":"Boulos","year":"2017","journal-title":"Int J Rheumatic Dis"},{"key":"10.1016\/j.amjms.2024.07.021_bib0033","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccm.2021.03.007","article-title":"Management of fibrotic hypersensitivity pneumonitis","volume":"42","author":"Barnes","year":"2021","journal-title":"Clin Chest Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924013569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924013569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T14:05:18Z","timestamp":1735826718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962924013569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0002962924013569"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2024.07.021","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of mycophenolate mofetil for the treatment of fibrotic hypersensitivity pneumonitis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2024.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}